Signals, Powered By EquityPandit
Cadila Healthcare has received final approval to market Carbidopa tablets,25 mg from USFDA.
The drug is used with a combination levodopa/carbidopa product to treat symptoms of Parkinson’s disease or Parkinson-like symptoms (such as shakiness, stiffness, difficulty moving) and will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.
Furthermore, the company’s board meeting will be held on May 25, 2018 to approve the audited financial results for the quarter/year ended on March 31, 2018 and to recommend dividend for the financial year ended on March 31, 2018.
